Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Iris Energy Limited (IREN) vs Mesoblast Limited (MESO) Price & Performance

Iris Energy LimitedTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Iris Energy Limited vs Mesoblast Limited — how do they compare? Iris Energy Limited trades at $42 (market cap $14.37B), while Mesoblast Limited trades at $16.36 (market cap $2.17B). The key difference: Iris Energy Limited is far larger — about 6.6× Mesoblast Limited's market cap. Which is the better fit depends on your goals.

IRENMESO
Market Cap
$14.37B$2.17B
Sector
EnergyTechnology
52-Week High
$76.41$20.96
52-Week Low
$15.40$12.88
Enterprise Value
$16.12B$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Iris Energy Limited

IREN trades at $40.20, up 19.57% in 24 hours but remains volatile amid a broader AI infrastructure stock sell-off. The stock shows a bearish technical signal with support at $31 and resistance at $36. Fundamentally, revenue grew to $501M in 2025 with a 20.88% net income margin, but recent quarters missed EPS expectations. The company is transitioning from Bitcoin mining to AI cloud services, with significant capital investment driving negative cash flow from investing activities.

Wall Street maintains a bullish stance with a $79.11 consensus price target and 71% buy ratings, citing IREN's AI infrastructure potential. However, execution risks, competitive pressures from Meta and peers, and recent earnings misses pose significant challenges. The stock's high valuation multiples (P/E 43.66) require flawless growth execution to justify current levels.

Mesoblast Limited

MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.

Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Iris Energy Limited

Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.

Read more on IREN

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO